A lowering of its Process Pillar rating is the primary driver of Fidelity Advisor® Biotechnology M's downgrade to a Morningstar Quantitative Rating of Neutral from Bronze. Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-highest quintile among peers.
- NAV / 1-Day Return 23.15 / 1.67 %
- Total Assets 1.8 Bil
-
Adj. Expense Ratio
- Expense Ratio 1.280%
- Distribution Fee Level Average
- Share Class Type Front Load
- Category Health
- Investment Style Mid Growth
- Min. Initial Investment 0
- Status Open
- TTM Yield 0.00
- Turnover 43%
Morningstar’s Analysis FBTTX
Will FBTTX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.